• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

American Academy of Neurology Annual Meeting

Patient Survey Suggests Preference for Once-Nightly Dosing With FT218 in Narcolepsy

April 27, 2022

Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.

NeuroVoices: Mark Lew, MD, on Exploring Reflex Tears as a Biomarker for Parkinson Disease

April 27, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.

Addition of Mechanical Thrombectomy Improves Odds of Good Outcome in Elderly Poststroke Patients

April 26, 2022

Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.

Aligning Patient, Clinician, and Caregiver Goals in Alzheimer Disease: Sharon Cohen, MD, FRCPC

April 26, 2022

The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]

Ozanimod Treatment Results in Higher Rates of No Evidence of Disease Activity vs Interferon ß-1a

April 25, 2022

After readjusting baseline to month 12, more patients with relapsing multiple sclerosis on continuous ozanimod achieved NEDA-3 and NEDA-4 status than those on interferon ß-1a.

Idiopathic Hypersomnia Demonstrates Moderate to Severe Impact on Quality of Life, Patient-Reported Outcomes

April 25, 2022

Despite a low percentage of patients missing work time due to their condition, a higher percentage reported impairment while working, overall work impairment, and activity impairment.

Treatment Optimization in Epilepsy and the Need to Individualize the Approach

April 24, 2022

Jacqueline A. French, MD, discussed the factors that influence the challenges in treatment selection in epilepsy, and how patient conversations and comprehension of heterogeneity can help in the treatment selection process.

Understanding the Effects of Polyunsaturated Fatty Acids on Multiple Sclerosis: Ludwig Kappos, MD, FEAN, FAAN

April 24, 2022

The professor of neurology at the University of Basel discussed a recent study presented at AAN 2022 on whether levels of polyunsaturated fatty acids are associated with MS disease activity or progression. [WATCH TIME: 4 minutes]

Ofatumumab Shows Decreased Effect on Microglial Activation in Relapsing Multiple Sclerosis

April 24, 2022

Patients treated with ofatumumab (Kesimpta; Novartis) demonstrated significant decreases in absolute and percent CD19 counts at day 5 of treatment, which persisted through the 90-day period.

Reasons for Selecting Certain Outcome Measures in Aducanumab’s Drug Development: Sharon Cohen, MD, FRCPC

April 22, 2022

The neurologist and assistant professor at the University of Toronto provided insight on the differences between outcome measures for Alzheimer disease and how they factored into a new item-level analysis of aducanumab (Aduhelm; Biogen). [WATCH TIME: 3 minutes]